KFDA approves autologous stem cell therapy for patients with Crohn’s disease

Anterogen, a Korean biotechnology venture, announced Tuesday that it will conduct phase I clinical trials in patients with Crohn’s disease with its autologous stem cell therapy from October 25 after obtaining its final approval from the Korea Food and Drug Administration.

Crohn’s disease causes chronic inflammation of intestines along with ulcers. Severe ulcers can create a fistula or tiny c...